|
|
|
Bionovo, Inc. (Nasdaq: BNVI) announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. In the trial, Bezielle showed an excellent safety and tolerability profile, and also showed promising indications of efficacy in a difficult-to-treat population. The Phase 1B clinical trial was conducted at eight US clinical sites under the directorship of Dr. Charles Shapiro, Professor of Medicine and
Director of Breast Oncology at Ohio State University. The primary objective of the study was to identify the maximum tolerated dose of Bezielle and to determine the safety, feasibility and preliminary efficacy of the Company"s novel, oral, anticancer therapy. A total of twenty-seven women with metastatic breast cancer were enrolled to the Phase 1B trial. To date, 48 women with advanced breast cancer have been successfully treated with Bezielle in two early clinical trials.
|
|
|
|
|
Boston"s health agency on Tuesday is scheduled to launch a safer-sex campaign that reaches out to teenagers through Web sites such as Facebook and YouTube, the Boston Globe reports. The campaign was created in response to rising rates of sexually transmitted infections among young people in the city, according to the Globe. The $100,000 campaign originally was intended to address communicable diseases in general. However, experts noticed the increase in STI cases among
teenagers and decided to spend all the funding on the campaign targeting STIs.The increase in chlamydia cases in particular demonstrates the "scope of the challenge," as 1,383 Boston youths between ages 15 and 19 were diagnosed with the STI in 2007, a 70% increase since 1999, the Globe reports.
|
|
|
|
|
Worldwide collaborative ties among researchers investigating the debilitating neurological condition multiple sclerosis (MS) have been strengthened thanks to the introduction of the first UK and Australian Fellowship Exchange programme. Dr Julia Morahan is the first person to be awarded the Macquarie Group Foundation Australia and UK MS Society Fellowship and she makes the move from investigating Motor Neurone Disease to research into MS. The initiative cements the relationship
between the UK MS Society and international scientists researching MS and is supported by the Macquarie Group Foundation - the philanthropic arm of Macquarie Group. Dr Lee Dunster, Head of Research and Information at the UK MS Society, said: "More than 2.5million people are living with MS around the world and there is some suggestion this number is rising.
|
|
|
|
|
States are grappling with budget cuts, trying to anticipate the effects of Washington"s health system overhaul and rejiggering Medicaid programs. Here"s a round-up of today"s local coverage: Boston Globe: "A unique state program that helps pay most health insurance costs for 27,000 unemployed Massachusetts residents is on the cusp of going broke, setting off a debate between healthcare advocates and business leaders who say funding it is a burden on companies
fighting for their survival." The program is financed by taxes; officials who oversee the program are expected to hike taxes to make up shortfalls in November (Lazar, 8/5). Idaho Statesman: "The state will buy all required childhood vaccines for all Idaho children through January 2010, whether their families have health insurance or not, Gov. Butch Otter announced Tuesday." The move comes after the state health department announced that insured children would no longer receive the free vaccines
due to budget cuts. The governor said the plan is not a "long-term solution," and said he hopes the legislation will come up with one (LaMay, 8/4).
|
|